4-(4-巯基苯基)苯甲腈 | 64409-12-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(4-巯基苯基)苯甲腈
• 英文名称: 4'-mercaptobiphenyl-4-carbonitrile
• 英文别名: 4-(4-mercaptophenyl)benzonitrile；4-(4-sulfanylphenyl)benzonitrile
• CAS: 64409-12-7
• 化学式: C₁₃H₉NS
• 分子量: 211.287
• InChiKey: ZZSHJNKMDIZSFY-UHFFFAOYSA-N

物化性质

• 熔点：
  127-132°C
• 沸点：
  384.5±35.0 °C(Predicted)
• 密度：
  1.21±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  24.8
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• WGK Germany：
  3

反应信息

• 作为反应物：
  描述：

  4-(4-巯基苯基)苯甲腈 在 吡啶 、 盐酸羟胺 、 potassium carbonate 作用下， 以 四氢呋喃 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 17.0h， 生成 4'-[3-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)-2-hydroxyiminopropylsufanyl]biphenyl-4-carbonitrile
  参考文献：
  名称：

  Phenoxyphenyl Sulfone N-Formylhydroxylamines (Retrohydroxamates) as Potent, Selective, Orally Bioavailable Matrix Metalloproteinase Inhibitors

  摘要：

  A novel series of sulfone N-formylhydroxylamines (retrohydroxamates) have been investigated as matrix metalloproteinases (MMP) inhibitors. The substitution of the ether linkage of ABT-770 (5) with a sulfone group 13a led to a substantial increase in activity against MMP-9 but was accompanied by a loss of selectivity for inhibition of MMP-2 and -9 over MMP-1 and diminished oral exposure. Replacement of the biphenyl P1' substituent with a phenoxyphenyl group provided compounds that are highly selective for inhibition of MMP-2 and -9 over MMP-1. Optimization of the substituent adjacent to the retrohydroxamate center in this series led to the clinical candidate ABT-518 (6), a highly potent, selective, orally bioavailable MMP inhibitor that has been shown to significantly inhibit tumor growth in animal cancer models.

  DOI：

  10.1021/jm0103920
• 作为产物：
  描述：

  氰基联苯酚 在 sodium hydroxide 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 17.67h， 生成 4-(4-巯基苯基)苯甲腈
  参考文献：
  名称：

  Phenoxyphenyl Sulfone N-Formylhydroxylamines (Retrohydroxamates) as Potent, Selective, Orally Bioavailable Matrix Metalloproteinase Inhibitors

  摘要：

  A novel series of sulfone N-formylhydroxylamines (retrohydroxamates) have been investigated as matrix metalloproteinases (MMP) inhibitors. The substitution of the ether linkage of ABT-770 (5) with a sulfone group 13a led to a substantial increase in activity against MMP-9 but was accompanied by a loss of selectivity for inhibition of MMP-2 and -9 over MMP-1 and diminished oral exposure. Replacement of the biphenyl P1' substituent with a phenoxyphenyl group provided compounds that are highly selective for inhibition of MMP-2 and -9 over MMP-1. Optimization of the substituent adjacent to the retrohydroxamate center in this series led to the clinical candidate ABT-518 (6), a highly potent, selective, orally bioavailable MMP inhibitor that has been shown to significantly inhibit tumor growth in animal cancer models.

  DOI：

  10.1021/jm0103920

文献信息

• BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA
  申请人：Merck Patent GmbH

  公开号：US20170210990A1

  公开（公告）日：2017-07-27

  The invention relates to bimesogenic compounds of formula I wherein R 11 , R 12 , MG 11 , MG 12 , X 11 , X 12 and Sp 1 have the meaning given in claim 1 , to the use of bimesogenic compounds of formula I in liquid crystal media and particular to flexoelectric liquid crystal devices comprising a liquid crystal medium according to the present invention.

  这项发明涉及式I的双向嵌段化合物，其中R11、R12、MG11、MG12、X11、X12和Sp1的含义如权利要求1所述，涉及在液晶介质中使用式I的双向嵌段化合物，特别涉及包括根据本发明的液晶介质的柔电液晶器件。
• Cyclic imino derivatives and pharmaceutical compositions containing them
  申请人：Karl Thomae GmbH

  公开号：US05541343A1

  公开（公告）日：1996-07-30

  The invention relates to cyclic imino compounds which have, inter alia, valuable pharmacological properties, especially inhibitory effects on cell aggregation, pharmaceutical compositions which contain these compounds and processes for preparing them.

  这项发明涉及具有有价值的药理特性，特别是对细胞聚集具有抑制作用的环亚胺化合物，包含这些化合物的药物组合物以及制备它们的方法。
• 3-Arylsulfonyl-2 (substituted methyl) propanoic acid derivatives as matrix metalloproteinase inhibitors
  申请人：Pharmacia Italia, SpA

  公开号：US06765003B1

  公开（公告）日：2004-07-20

  Compounds which are 3-arylsulfonyl-2-methyl propanoic acid derivatives of formula (I): wherein X is HO—NH— or HO—, R1 is selected from phenyl, 4-chlorophenyl, 4-florophenyl, 4-cyanophenyl, benzamido (i.e., —NH—CO-Ph) and benzamido substituted on the terminal phenyl ring by C1-C4 alkyl, fluoro, chloro, cyano or C1-4 alkoxy; R2 is selected from (a) —S—Ar or —S—CH2—Ar wherein Ar is an aromatic moiety; (b) —O—Ar wherein Ar is as defined above; (c) —S-Het or —S—CH2-Het wherein Het is a heterocyclic ring; and (d) 2,5-dioxo-1-imidazolidinyl or 2,4-dioxo-1-imidazolinyl; and the pharmaceutically acceptable salts thereof; have potent and selective inhibitory activity against matrix metalloproteinases (MMPs) and can thus be used in the treatment and prevention of diseases mediated by MMPs.

  化合物是公式(I)的3-芳基磺酰基-2-甲基丙烯酸衍生物，其中X为HO—NH—或HO—，R1从苯基、4-氯苯基、4-氟苯基、4-氰苯基、苯甲酰氨基（即，—NH—CO-Ph）和苯甲酰氨基中选择，其在末端苯环上被C1-C4烷基、氟、氯、氰或C1-4烷氧基取代；R2从(a) —S—Ar或—S—CH2—Ar中选择，其中Ar是芳香基；(b) —O—Ar，其中Ar如上所定义；(c) —S-Het或—S— -Het，其中Het是杂环环；和(d) 2,5-二氧杂-1-咪唑烷基或2,4-二氧杂-1-咪唑烷基；以及其药学上可接受的盐；具有对基质金属蛋白酶（MMPs）具有强效和选择性抑制活性，因此可用于治疗和预防由MMPs介导的疾病。
• Hydroxylamine‐Derived Reagent as a Dual Oxidant and Amino Group Donor for the Iron‐Catalyzed Preparation of Unprotected Sulfinamides from Thiols
  作者：Sayanti Chatterjee、Szabolcs Makai、Bill Morandi

  DOI：10.1002/anie.202011138

  日期：2021.1.11

  An iron catalyzed reaction for the selective transformation of thiols (‐SH) to sulfinamides (‐SONH2) by a direct transfer of ‐O and free ‐NH2 groups has been developed. The reaction operates under mild conditions using a bench stable hydroxylamine derived reagent, exhibits broad functional group tolerance, is scalable and proceeds without the use of any precious metal catalyst or additional oxidant

  开发了一种铁催化反应，通过直接转移-O和游离-NH 2基团，将硫醇（-SH）选择性转化为亚磺酰胺（-SONH 2 ）。该反应使用工作台稳定的羟胺衍生试剂在温和条件下进行，表现出广泛的官能团耐受性，可扩展且无需使用任何贵金属催化剂或额外的氧化剂即可进行。这种新颖、实用的反应可一步形成两个不同的新键（S=O 和 S−N），从而化学选择性地形成有价值的、未受保护的亚磺酰胺产物。初步的机理研究表明醇溶剂作为氧原子供体的作用。
• [EN] INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER<br/>[FR] DÉRIVÉS D'INDOLE ET LEURS UTILISATIONS POUR LE TRAITEMENT D'UN CANCER
  申请人：UNIV CLAUDE BERNARD LYON

  公开号：WO2022008475A1

  公开（公告）日：2022-01-13

  The present invention relates to indole derivatives of formula (I') as CK2 inhibitor and pharmaceutical compositions comprising the same. The present invention further relates to the use of such compounds of formula (I) for use for preventing and/or treating a cancer.

  本发明涉及一种具有如下式（I'）的吲哚衍生物作为CK2抑制剂，以及包含该衍生物的药物组合物。本发明还涉及利用该式（I）化合物用于预防和/或治疗癌症的用途。